


Provided for non-commercial research and education use.
Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/copyright>



Contents lists available at ScienceDirect

Clinica Chimica Acta

journal homepage: www.elsevier.com/locate/clinchim

Letter to the editor

Fractions of plasma gamma-glutamyltransferase in healthy individuals: Reference values

Dear Editor,

Gamma-glutamyltransferase (GGT) activity, long used as a biomarker of liver function and excessive alcohol use [1], has been recently recognized to be a biomarker of future occurrence of diabetes and cardiovascular events [2–3], either in unselected populations [4], or in patients with ascertained ischemic heart disease [5]. Although the assay is widely used, highly reproducible and sensitive, it holds a poor specificity [1].

We recently set up a novel, highly reproducible and sensitive method for differentiating and quantifying four GGT activity fractions (“big”, “medium”, “small” and “free”: b-, m-, s-, and f-GGT, respectively) in human blood [6], by means of molecular exclusion chromatography. We aimed to assess the clinical potential of the method by establishing reference values in healthy subjects.

Fasting blood samples were obtained between 8:00 and 9:00 from 200 healthy individuals [blood donors, 100 males, mean \pm SD, age 44 ± 10 years (range, 21–64), 100 females, age 40 ± 11 years (range 20–64)]. The presence of acute or chronic diseases, and of metabolic syndrome (according to World Health Organisation criteria [7]) was excluded by history, clinical examination and comprehensive laboratory testing. Subjects on pharmacological treatment for whatever reasons or with alcohol consumption >45 g/day for men and >30 g/day for women were previously excluded from the study. The study was approved by the Institutional Ethics Committee and all subjects gave informed consent.

Total and fractional GGT analysis was performed on plasma–EDTA samples as described previously [9], by using an FPLC system (AKTA purifier, GE Healthcare) equipped with a gel-filtration column (Jasosep 6 HR 10/300 GL, GE Healthcare) and a fluorescence detector (Jasco FP-2020). GGT activity determination performed on plasma–EDTA samples showed a correlation coefficient of 0.99 ($n=10$) with values obtained either in serum or in plasma–heparin samples. Inter-assay CV% was 4.65 for total GGT, 6.19 for b-GGT, 5.13 for m-GGT, 4.66 for s-GGT, 4.77 for f-GGT. Fractional GGT area was calculated with the aid of a computer program (MATLAB Version 7 MathWorks, Inc.) to resolve overlapping peaks, the curve fitting was conducted with a nonlinear least-squares minimization algorithm using four exponentially modified Gaussian (EMG) curves; upper and lower bounds for the curve amplitude, width, position and asymmetry were set for each peak.

Our original procedure allowed the analysis of four GGT fractions in all plasma samples examined, overcoming the low sensitivity of previously proposed methods, which cannot give homogeneous nor reproducible results [8–10]. All four GGT fractions showed significantly higher values in males than in females (Table 1). In both genders total plasma GGT, as well as b-, m- and s-GGT fractions, showed a right-skewed distribution, while f-GGT showed a normal

distribution ($P>0.10$, Kolmogorov–Smirnov test with Dallal–Wilkinson–Lillie for P value).

Plasma GGT fraction analysis might help to specify the complex interaction between GGT activity and cardiovascular risk factors. We have found in healthy subjects of both genders that f-GGT fraction, with a molecular weight of 70 kDa, is the prominent one for total GGT values in the low-normal range (below median; males: <25 U/l, females: <14 U/l) (Fig. 1). For total GGT levels above median values, known to be associated with cardiovascular risk factors such as BMI, DAP, serum triglycerides and LDL cholesterol [4], we observed a consistent logarithmic increase in b-, m- and s-GGT fractions (Fig. 1), whose molecular weights are respectively in the range of VLDL, LDL and HDL [9]. Nevertheless, the relationship between fractional GGT, lipoproteins and cardiovascular disorders needs further characterization.

In conclusion, GGT fraction analysis by high performance molecular exclusion chromatography could improve the low specificity of current GGT assay, allowing the discrimination of underlying risk and/or pathologic conditions.

References

- [1] Whitfield JB. Gamma glutamyl transferase. *Crit Rev Clin Lab Sci* 2001;38:263–355.
- [2] Lim JS, Lee DH, Park JY, Jin SH, Jacobs Jr DR. A strong interaction between serum gamma-glutamyltransferase and obesity on the risk of prevalent type 2 diabetes: results from the Third National Health and Nutrition Examination Survey. *Clin Chem* 2007;53:1092–8.
- [3] Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. *Arterioscler Thromb Vasc Biol* 2007;27:127–33.
- [4] Ruttman E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. gamma-Glutamyltransferase as a risk factor for cardiovascular disease mortality. An investigation in a cohort of 163,944 Austrian adults. *Circulation* 2005;112:2130–7.
- [5] Emdin M, Passino C, Michelassi C, et al. Prognostic value of serum gamma-glutamyltransferase activity after myocardial infarction. *Eur Heart J* 2001;22:1802–7.
- [6] Franzini M, Bramanti E, Ottaviano V, et al. A high performance gel filtration chromatography method for gamma-glutamyltransferase fraction analysis. *Anal Biochem* 2008;374:1–6.
- [7] Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998;15:539–53.
- [8] Sacchetti L, Castaldo G, Salvatore F. The gamma-glutamyltransferase isoenzyme pattern in serum as a signal discriminating between hepatobiliary diseases, including neoplasias. *Clin Chem* 1988;34:352–5.

Table 1
Total and fractional plasma GGT activities in healthy humans

	Males (n=100)		Females (n=100)		P
	Median	5th–95th percentile	Median	5th–95th percentile	
Total GGT*	25.3	12.3–60.5	14.4	8.4–30.9	<0.001
b-GGT*	2.4	0.7–10.7	1.1	0.4–5.2	<0.0001
m-GGT*	1.0	0.2–3.3	0.5	0.2–1.2	<0.0001
s-GGT*	9.2	2.8–33.7	3.9	1.5–11.6	<0.0001
f-GGT	13.2	8.3–19.6	8.9	5.9–12.5	<0.0001

Data are expressed as U/l. *Student's t -test performed on ln transformed data. N.S.: not significant.




Fig. 1. Elution profile of fractional GGT activity corresponding to the 25th (dashed line), 50th (solid line) and 75th (dotted line) percentile of total GGT in healthy males (A, $n = 100$) and healthy females (B, $n = 100$). Fractional GGT analysis was performed on plasma-EDTA samples by high performance gel-filtration chromatography, GGT activity was specifically detected by an on-line post-column reaction with a fluorescent substrate, γ GluAMC [6].

- [9] Pompili M, Addolorato G, Pignataro G, et al. Evaluation of the albumin- γ -glutamyltransferase isoenzyme as a diagnostic marker of hepatocellular carcinoma-complicating liver cirrhosis. *J Gastr Hep* 2003;18:288-95.
 [10] Bellini M, Tumino E, Giordani R, et al. Serum γ -glutamyl-transpeptidase isoforms in alcoholic liver disease. *Alcohol Alcohol* 1997;32:259-66.

Maria Franzini^{*,1}

Claudio Passino

Scuola Superiore Sant'Anna, Pisa, Italy

E-mail address: m.franzini@sssup.it (K. Kotani).

* Corresponding author. Scuola Superiore Sant'Anna, C.N.R. Institute of Clinical Physiology, Via Giuseppe Moruzzi 1, 56124 Pisa, Italy. Tel.: +39 050 3153309; fax: +39 050 3152166.

Virginia Ottaviano

Vanna Fierabracci

Alfonso Pompella¹

Aldo Paolicchi¹

Department of Experimental Pathology, University of Pisa, Italy

Emilia Bramanti

CNR Institute of Chemico-Physical Processes, Pisa, Italy

Luc Zyw

Claudio Boni

Chiara Mammini

Michele Emdin¹

Claudio Passino

Cardiovascular Medicine Department, Foundation G. Monasterio,

CNR Institute of Clinical Physiology, Pisa, Italy

Renata Barsacchi

Department of Biology University of Pisa, Italy

Fabrizio Scatena

UO Immunoematologia 2, Azienda Ospedaliera Universitaria Pisana,

Pisa, Italy

29 May 2008

¹ These authors equally contributed to the study.